在晚期前列腺癌患者中评价镥[177Lu]JH020002注射液的安全性、耐受性、辐射剂量学和抗肿瘤活性的多中心、开放、非随机的I/II期临床试验
[Translation] A multicenter, open-label, non-randomized phase I/II clinical trial to evaluate the safety, tolerability, radiation dosimetry, and antitumor activity of lutetium [177Lu] JH020002 injection in patients with advanced prostate cancer
评价镥[177Lu]JH020002注射液治疗转移性前列腺癌的安全性和耐受性,并探索镥[177Lu]JH020002注射液的最大耐受剂量(MTD),为后续研究提供推荐剂量(RP2D)(I期);评价镥[177Lu]JH020002注射液治疗转移性前列腺癌的抗肿瘤活性(II期)。
[Translation] To evaluate the safety and tolerability of lutetium [177Lu] JH020002 injection in the treatment of metastatic prostate cancer, explore the maximum tolerated dose (MTD) of lutetium [177Lu] JH020002 injection, and provide a recommended dose (RP2D) for subsequent studies (Phase I); to evaluate the anti-tumor activity of lutetium [177Lu] JH020002 injection in the treatment of metastatic prostate cancer (Phase II).
100 Clinical Results associated with Crystal Nucleus Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Crystal Nucleus Biomedical Technology Co., Ltd.
100 Deals associated with Crystal Nucleus Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Crystal Nucleus Biomedical Technology Co., Ltd.